MedX Health raised $2 million to develop a dermatology analysis and evaluation system

Medical device company MedX Health is understood to have announced a non-broker private placement to raise $2m.
MedX will use this funding to develop a noninvasional dermatology analysis and evaluation system to improve patient quality of life and care services.
MedX has developed medical devices such as phototherapy equipment and imaging systems for use by trained medical professionals. The company hopes to use advanced technology to improve patient care and improve medical care.
In its early days, MedX was dedicated to the study of photomodulation (PBM) and to the development, manufacture and distribution of light therapy-related medical devices. These devices are mainly used in rehabilitation and dentistry, and their adaptations include pain, tissue damage, swelling and inflammation, providing effective, non-toxic and non-invasive treatment options for patients.
Light therapy is the use of sunlight or infrared, ultraviolet, visible light, laser and other artificial light to prevent diseases and promote the recovery of the body, the current solar therapy has been classified into the category of convalescy.
In 2011, MedX introduced SIAscopy technology-related assets and businesses for scanning moles and skin lesions. The technology explores 2 mm below the skin in a painless and invasible way and uses the software to create real-time images for dermatologists. SIAscopy technology is highly efficient and can detect all types of moles or skin lesions in a very short time.
Skin cancer is the most common cancer in the world, with more than 13 million confirmed cases each year, of which about 60,000 die. The rate of diagnosis of melanoma in these diseases is rising rapidly, surpassing even the seven most common cancers, such as prostate and breast cancer. Nevertheless, most skin cancer patients can be cured through prevention and early screening.
MedX created the DermSecure telemedicen platform based on SIAscopy technology. In addition, the technology is embedded in medical devices such as SIAMETRICS, SIMSYS and MoleMate. These SIAscopy-based products have been approved by Health Canada and the FDA and are CE-certified and listed in Canada, the United States, Australia, New Zealand, the European Union and Turkey. (Arterial mesh)